Retinoblastoma seeds: impact on American Joint Committee on Cancer clinical staging

CHANTADA G; SCHAIQUEVICH P

BRITISH JOURNAL OF OPHTHALMOLOGY

B M J PUBLISHING GROUP

Lugar: Londres; Año: 2021

0007-1161

ABSTRACTAim To investigate whether the American JointCommittee on Cancer (AJCC) clinical category cT2bneeds to be subclassified by the type and distribution ofretinoblastoma (RB) seeding.Methods Multicentre, international registry-baseddata were collected from RB centres enrolled betweenJanuary 2001 and December 2013. 1054 RB eyeswith vitreous or subretinal seeds from 18 ophthalmiconcology centres, in 13 countries within six continentswere analysed. Local treatment failure was definedas the use of secondary enucleation or external beamradiation therapy (EBRT) and was estimated with theKaplan-Meier method.Results Clinical category cT2b included 1054 eyes.Median age at presentation was 16.0 months. Of these,428 (40.6%) eyes were salvaged, and 430 (40.8%) weretreated with primary and 196 (18.6%) with secondaryenucleation. Of the 592 eyes that had complete datafor globe salvage analysis, the distribution of seedswas focal in 143 (24.2%) and diffuse in 449 (75.8%).The 5-year Kaplan-Meier cumulative globe-salvage(without EBRT) was 78% and 49% for eyes with focaland diffuse RB seeding, respectively. Cox proportionalhazards regression analysis confirmed a higher localtreatment failure risk with diffuse seeds as comparedwith focal seeds (hazard rate: 2.8; p